Sixty Sessions of Hyperbaric Oxygen Lengthened Telomeres by a Third. There Were Twenty-Five People and No Control Group.
In November 2020 a group at the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center in Israel published a paper with a title that did most of the marketing on its own. Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells. Thirty-five healthy adults over 64, sixty daily sessions in a pressurized chamber, and average telomere length in four types of immune cell rising by more than a fifth, in one case by more than a third. Within a week the finding had been compressed into a sentence that has been circulating ever since, which is that hyperbaric oxygen reverses two hallmarks of aging in humans. The paper itself is more careful than its afterlife. It lists a small sample, no control group, unknown duration of effect and no telomerase measurement among its own limitations. It also reports a second finding, a 37 percent drop in senescent T helper cells, that offers a mundane explanation for the first one. Average telomere length across a population of cells goes up if the cells with the shortest telomeres stop being part of the population, and nothing has to grow for that to happen. This is an educational review of what the hyperbaric oxygen aging evidence actually shows, what the randomized trials in the same population reported, and where the case stops.
Key Takeaways: What the Hyperbaric Oxygen Aging Evidence Actually Shows
Hyperbaric oxygen therapy delivers 100 percent oxygen at pressure greater than sea level, which dissolves far more oxygen into blood plasma than breathing air can, and the aging protocol used in the Israeli trials is 60 daily sessions of 90 minutes at 2 atmospheres absolute with five-minute air breaks every 20 minutes, run five days a week for three months. Hachmo and colleagues reported in Aging in November 2020 that in 35 healthy adults aged 64 and older, average telomere length measured by flow-FISH in isolated peripheral blood mononuclear cells rose by about 37.6 percent in B cells, 29.3 percent in T helper cells, 22.2 percent in natural killer cells and 19.6 percent in cytotoxic T cells at one to two weeks after the course finished. The telomere analysis in that paper included 25 participants rather than 35, the senescence analysis included 20, and there was no control group, which the authors list as a limitation alongside the fact that telomerase activity was never measured. The same paper reported that senescent T helper cells fell by about 37.3 percent and senescent cytotoxic T cells by about 11.0 percent, a result that is interesting on its own and that also supplies an alternative explanation for the telomere number, because removing short-telomere cells from a mixed population raises the population average without lengthening a single telomere. Efrati and colleagues reported in Aging in June 2020 a genuinely randomized trial in 63 healthy adults over 64, assigning 33 to hyperbaric oxygen and 30 to a control arm, finding a significant group-by-time interaction for global cognitive function at p equals 0.0017 with net effect sizes of 0.788 for information processing speed and 0.745 for attention, alongside increased cerebral blood flow on perfusion magnetic resonance imaging. Hadanny and colleagues reported in BMC Geriatrics in 2024 a randomized trial in the same age group that raised maximal oxygen consumption by 1.91 millilitres per kilogram per minute with a net effect size of 0.455, raised oxygen uptake at the first ventilatory threshold by 160 millilitres per minute with an effect size of 0.617, and increased myocardial blood flow and blood volume against control. A skin biopsy study published in Aging in 2021 examined 13 men aged about 68 who served as their own controls through a three-month no-treatment period, reporting increased collagen density with an effect size of 1.10, increased elastic fiber length with an effect size of 2.71 and fewer tissue senescent cells with an effect size of 0.84 after hyperbaric oxygen. Mendelian randomization studies using inherited telomere-length variants consistently find that genetically longer telomeres associate with higher risk of lung adenocarcinoma, glioma, melanoma, renal cell carcinoma and several lymphoid cancers, with lung adenocarcinoma odds ratios near 1.9 per additional 1,000 base pairs, so telomere lengthening is not an unambiguously favorable direction. Regulators have cleared hyperbaric oxygen for roughly 14 medical indications including decompression sickness, carbon monoxide poisoning, diabetic foot ulcers, delayed radiation injury and sudden sensorineural hearing loss, and aging is not among them, with the United States Food and Drug Administration having issued public warnings about clinics marketing unapproved uses. Middle ear barotrauma is the most common adverse event, reversible myopia has been reported in 25 to 100 percent of patients on courses of several weeks at 2.0 atmospheres or more, and central nervous system oxygen toxicity seizures occur in roughly 0.01 to 0.05 percent of treatments. A 60-session course is 90 hours of chamber time across three months and, at typical United States independent-clinic pricing of roughly 150 to 250 dollars per session, a five-figure cash expense, because no insurer covers hyperbaric oxygen for aging. No trial of hyperbaric oxygen has measured lifespan, mortality, frailty or any hard aging endpoint, and no independent group has replicated the 2020 telomere finding.
What Did the 2020 Hyperbaric Oxygen Telomere Study Actually Do?
It put 35 healthy adults over 64 through 60 daily hyperbaric oxygen sessions across three months and measured telomere length in their blood cells four times. The protocol was specific and worth stating precisely, because the pressure and the session count are what separate this work from the soft-shell chambers sold for home use. Participants breathed 100 percent oxygen through a mask at 2 atmospheres absolute for 90 minutes, with a five-minute air break every 20 minutes, five sessions a week for three months. The air breaks are not incidental. They are the standard method for reducing pulmonary and central nervous system oxygen toxicity during long exposures. Blood was drawn at baseline, at the 30th session, at the 60th session and again one to two weeks after the last session. Telomere length was measured by flow-FISH, a technique that hybridizes a fluorescent probe to telomere repeats and reads the signal by flow cytometry, on isolated peripheral blood mononuclear cells sorted into B cells, T helper cells, cytotoxic T cells and natural killer cells. The reported gains at the final measurement were about 37.6 percent for B cells, 29.3 percent for T helper cells, 22.2 percent for natural killer cells and 19.6 percent for cytotoxic T cells, with the cytotoxic T cell change at session 30 falling short of significance. Two details of the analysis matter as much as the percentages. Telomere data came from 25 participants and senescence data from 20, because samples of insufficient quality were excluded. And there was no control arm, so every one of those percentages is a within-person change over three months with nothing running alongside it.
Twenty to Thirty-Eight Percent, in Twenty-Five People
Percent change from baseline in average telomere length measured by flow-FISH in isolated peripheral blood mononuclear cells, reported by Hachmo and colleagues in Aging in November 2020. Thirty-five healthy adults aged 64 and older received 60 daily hyperbaric oxygen sessions over three months, and telomere data were analyzed in 25 of them. Blood was drawn at baseline, at the 30th session, at the 60th session, and again one to two weeks after the course ended. The B cell increase was the largest at about 37.6 percent post-course. The T cytotoxic change at session 30 did not reach statistical significance.
- After 30 sessions
- After 60 sessions
- One to two weeks after
Did the Telomeres Get Longer, or Did the Short Ones Leave?
The study cannot tell those two possibilities apart, and this is the single most important thing to understand about the result. Flow-FISH on a sorted cell population reports an average telomere length across the cells in that population. That average rises if individual telomeres physically elongate. It also rises if the cells carrying the shortest telomeres disappear from the sample, because the surviving cells were always the ones with longer telomeres. In an aging immune system, the cells with the shortest telomeres are disproportionately the senescent and highly differentiated ones. The same paper reported that senescent T helper cells dropped by about 37.3 percent and senescent cytotoxic T cells by about 11.0 percent over the treatment course. The authors present this as a second benefit, and it may well be one, since senescent cell burden is a plausible target in its own right. It is also exactly the mechanism that would produce a telomere number like this one without any telomere growing at all. A shift in the mix toward naive lymphocytes, which carry longer telomeres than memory and effector cells, would do the same thing. Settling this would require measuring telomerase activity, which the authors state was not done, or tracking telomere length within an individually identified cell population over time. Neither experiment has been published for this protocol. That does not make the finding wrong. Senescent cell clearance and telomere maintenance are both reasonable things for a strong oxidative and hypoxic stimulus to influence, and the hyperoxic-hypoxic paradox that the Israeli group proposes as the mechanism is a coherent hypothesis. It means the headline as usually repeated, that hyperbaric oxygen lengthens human telomeres, is one interpretation of an ambiguous measurement rather than an established fact.
Longer Telomeres, or Fewer Cells With Short Ones
A schematic map of what the 2020 telomere result can and cannot distinguish. Blue marks what the study measured directly, amber marks explanations that fit the same data without any telomere actually growing, slate marks the design limits the authors themselves listed, and dark grey marks the experiments nobody has run. Average telomere length across a population of blood cells rises if the short-telomere cells leave the population, and the same paper reported that senescent T helper cells fell by about 37 percent. Both findings are consistent with elongation and with selective clearance, and flow-FISH on a mixed cell population cannot separate the two.
Why Does the Missing Control Group Matter So Much Here?
Because without a control arm there is no way to separate the treatment from everything else that happened to these participants over three months. Sixty visits to a research center is not a passive experience. Participants changed their daily routine, spent 90 minutes at a time resting, interacted repeatedly with clinical staff, and knew exactly what they were receiving and what it was supposed to do. Blood cell composition also moves with season, with infection, with sleep and with activity. A single-arm design attributes all of that to the intervention by default. The group did run properly randomized trials on other outcomes, which makes the absence here more conspicuous rather than less. There is also a cautionary example from a different question entirely. The HOT-LoCO trial from Karolinska University Hospital, published in 2025, randomized 80 people with long COVID to hyperbaric oxygen or a sham exposure under double-blind conditions and found that both groups improved at 13 weeks with no significant difference between them. That trial used 10 sessions rather than 60 and asked about symptoms rather than cell biology, so it does not refute anything in the aging work. It is a demonstration that hyperbaric oxygen studies with a credible sham can return null results where uncontrolled ones return large ones, which is the general pattern across medicine and the reason the control arm is not a formality.
What Did the Randomized Hyperbaric Oxygen Trials in Older Adults Find?
Two randomized trials in adults over 64 hit their endpoints, and neither of them measured telomeres. Efrati and colleagues published a randomized controlled trial in Aging in June 2020 that assigned 63 healthy older adults to hyperbaric oxygen or a control condition for three months, 33 to treatment and 30 to control, using the same 60-session protocol. Global cognitive function showed a significant group-by-time interaction at p equals 0.0017, with the largest net effect sizes in attention at 0.745 and information processing speed at 0.788. Perfusion magnetic resonance imaging showed increased cerebral blood flow, with a significant rise in the parietal gyrus. That is a real mechanism visible on imaging rather than a subjective questionnaire result. Hadanny and colleagues published a second randomized trial in BMC Geriatrics in 2024 in the same population, this time measuring physical capacity. Maximal oxygen consumption rose by 1.91 millilitres per kilogram per minute with a net effect size of 0.455, and oxygen uptake at the first ventilatory threshold rose by 160 millilitres per minute with a net effect size of 0.617. Myocardial blood flow and blood volume both increased against control. A separate skin biopsy study published in Aging in 2021 followed 13 men aged about 68 through a three-month no-treatment period and then three months of hyperbaric oxygen, reporting increased collagen density, longer elastic fibers, more blood vessels, less fiber fragmentation and fewer tissue senescent cells. That last study used each participant as his own control rather than randomizing, and 13 people is a very small number for effect sizes as large as the ones reported, so it belongs in a different tier of evidence from the two randomized trials. Read together, these results say something consistent and narrower than the telomere headline. Repeated hyperbaric exposure appears to increase tissue perfusion and to produce measurable gains in cognitive and cardiorespiratory performance in older adults over three months. None of these trials followed anyone for years, and none measured whether any of it changes how long or how well people live.
The Trials That Did Have a Control Group
Reported effect sizes from the controlled hyperbaric oxygen studies in older adults run by the Sagol Center group in Israel. Blue marks outcomes from randomized trials: the 2020 cognition trial randomized 63 adults over 64 and reported net effect sizes of 0.788 for information processing speed and 0.745 for attention, and the 2024 BMC Geriatrics trial in the same population reported 0.617 for oxygen uptake at the first ventilatory threshold and 0.455 for maximal oxygen consumption. Amber marks the skin biopsy findings, which came from 13 men who served as their own controls across a three-month no-treatment period rather than from randomization, so the large effect sizes there carry much less weight than their size suggests.
Is a Longer Telomere Always a Good Thing?
No, and this is the part of the telomere story that rarely appears next to the marketing. Short telomeres are associated with cellular senescence and with several degenerative conditions, which is why lengthening them sounds unambiguously desirable. The genetic evidence points in a more complicated direction. Mendelian randomization studies use inherited variants that influence telomere length as a natural experiment, which sidesteps the reverse-causation problems that plague observational telomere research. Those studies consistently find that genetically longer telomeres associate with higher risk of several cancers, including lung adenocarcinoma with odds ratios near 1.9 per additional 1,000 base pairs, along with glioma, melanoma, renal cell carcinoma, chronic lymphocytic leukemia and certain B-cell lymphomas. The biological logic is not mysterious. Telomere shortening is one of the brakes that stops a damaged cell from dividing indefinitely, and releasing that brake is a step most cancers have to take. There are two honest qualifications. These findings describe lifelong inherited telomere length, not a three-month change induced in adulthood, and nobody has tested whether an induced change carries the same association. And a telomere measurement in circulating blood cells is a poor proxy for what is happening in the tissues where cancers actually start. The point is not that hyperbaric oxygen causes cancer, because no evidence says that. The point is that telomere length is a biomarker whose optimal direction is genuinely contested, so an intervention that moves it is not automatically moving it the right way.
The Direction Nobody Puts on the Marketing Page
Approximate odds ratios for cancer risk associated with genetically longer telomeres, drawn from Mendelian randomization analyses that use inherited telomere-length variants as a natural experiment. Longer telomere length behaves as a risk factor rather than a protective factor for several cancers, with lung adenocarcinoma the strongest and most replicated signal at roughly 1.9 per 1,000 base pairs of additional length. The dashed line marks an odds ratio of 1.0, meaning no association. These figures describe lifelong inherited telomere length rather than a three-month intervention, and no study has tested whether an induced change carries the same risk, which is precisely the point: the biology of telomere lengthening is not unambiguously in your favor.
What Does a 60-Session Course Actually Cost in Time, Money and Risk?
Ninety hours in a chamber across three months, a five-figure cash expense in most United States markets, and a side effect profile that is well characterized rather than trivial. The time commitment is the part people underestimate. Sixty sessions at 90 minutes, five days a week, is a daily appointment for twelve consecutive weeks, and the protocol used in every one of the Israeli aging studies is exactly that. The pressure also matters. These trials ran at 2 atmospheres absolute with a medical-grade mask, which is not what a 1.3 atmosphere soft-shell chamber in a wellness studio delivers, and results from one do not transfer to the other. On cost, United States pricing for hyperbaric oxygen outside covered indications typically runs around 150 to 250 dollars a session at independent clinics and higher in hospital settings, which puts a full 60-session course in five figures before any package discount. No insurer pays for it as an aging intervention, because no regulator has cleared it for that. Regulators have cleared hyperbaric oxygen for roughly 14 indications, among them decompression sickness, arterial gas embolism, carbon monoxide poisoning, gas gangrene, crush injury, problem wounds including diabetic foot ulcers, delayed radiation injury, refractory osteomyelitis, compromised grafts and sudden sensorineural hearing loss. The United States Food and Drug Administration has issued consumer warnings and a letter to health care providers specifically because clinics market the therapy for uses it has not been cleared for, aging among them. The adverse events are predictable and mostly pressure-related. Middle ear barotrauma is the most common, and ear clearing technique and slow compression are the standard mitigations. Reversible myopia is very common on long courses, reported across a wide range in the literature after several weeks at 2.0 atmospheres or more, and it typically resolves over weeks to months after treatment ends, though very long courses have been associated with cataract progression. Central nervous system oxygen toxicity seizures are rare, on the order of 0.01 to 0.05 percent of treatments, which is the reason for the air breaks built into the protocol. Confinement anxiety, sinus pain and hypoglycemia in people on diabetes medication round out the common list. Untreated pneumothorax and certain chemotherapy exposures are contraindications, which is why this is a physician-supervised medical treatment rather than a spa service.
How Does This Compare With Peptide Approaches to Telomeres?
Hyperbaric oxygen has by far the stronger human trial record, and both approaches share the same unresolved measurement problem. Peptides marketed for telomere maintenance, epitalon among them, rest largely on cell culture work, animal studies and a small body of older clinical literature, with no modern randomized controlled trial measuring telomere length in humans against a placebo arm. Hyperbaric oxygen at least has two randomized trials in adults over 64 with pre-specified endpoints, imaging-confirmed mechanisms and published effect sizes, which is more than almost any compound in the longevity conversation can claim. That comparison flatters hyperbaric oxygen, and it should not be read as an endorsement of the telomere claim specifically, because the telomere claim is the weakest part of its own evidence base. The shared problem is what a telomere number in circulating blood cells means. Any intervention that changes the composition of the immune cell pool will change the measured average, whether it is a peptide, a pressurized chamber, an illness or a training block. Until a study measures telomerase activity, tracks defined cell populations over time and runs a control arm, a percentage change in average telomere length is a finding in search of an interpretation. Anyone comparing these options should be comparing the quality of the underlying trials rather than the size of the percentage in the headline, and neither approach has produced evidence that a telomere change translates into living longer or better.
How Should a Man Read the Hyperbaric Oxygen Evidence Right Now?
As a real medical intervention with better randomized data than most longevity candidates, attached to a specific headline claim that its own study design cannot support. The case for taking hyperbaric oxygen seriously is genuine. Two randomized trials in adults over 64 met their endpoints on cognition and on cardiorespiratory capacity, with effect sizes in the moderate to large range and mechanisms visible on perfusion imaging rather than inferred. It is a regulated treatment delivered under physician supervision with a decades-long safety record in its cleared indications and a well-mapped adverse event profile. The skin biopsy work, small as it is, found structural tissue changes rather than self-reported improvement. The case for restraint is equally concrete. The telomere result that drives most of the public interest came from 25 people with no control group, used a measurement that cannot distinguish elongation from selective clearance of short-telomere cells, did not measure telomerase, and has not been replicated by an independent group in the years since publication. Longer telomeres are associated with higher risk of several cancers in the genetic evidence, so the direction of benefit is not settled even if the change is real. No hyperbaric oxygen trial has measured lifespan, mortality or frailty. The protocol behind every one of these results is 60 sessions of 90 minutes at 2 atmospheres across three months, which is a substantial commitment of time and money that a lower-pressure chamber does not reproduce. And no regulator has cleared the therapy for aging, which is why the marketing that surrounds it has drawn formal warnings. The reasonable posture is to treat hyperbaric oxygen as a serious intervention with promising short-term functional data and an unresolved biological headline, to be skeptical of any clinic quoting the telomere number without the design caveats, and to have any conversation about it with a physician who can assess ear and lung status, medication interactions and whether a cleared indication actually applies. This article is educational and is not medical advice.
The Hyperbaric Oxygen Record on One Axis
Every strand of the hyperbaric oxygen aging case arranged as a single schematic map. Blue marks what the evidence supports, amber marks findings and burdens that are real but narrower or more costly than the headline suggests, slate marks results that count against the intervention, and dark grey marks claims the evidence does not carry. Hyperbaric oxygen is a genuinely regulated medical treatment with randomized data in older adults and a mechanism visible on perfusion imaging. It is also a three-month, sixty-session, five-figure commitment whose most quoted result came from twenty-five people with nothing to compare them against.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
Does Telomere Length Determine Lifespan? Short Telomeres Track With Earlier Death. The Genetics Say Longer Ones Raise Cancer Risk.
Does telomere length determine lifespan? Short telomeres track with earlier death, yet genetic studies show longer ones raise the risk of several cancers.
Low-Dose Aspirin Added 8 Percent to Male Mouse Lifespan. In 19,114 Healthy Older Adults, It Added No Healthy Years and Deaths Ran Higher.
Does low-dose aspirin help longevity? It extended male mouse lifespan 8%, but the ASPREE trial in 19,114 healthy older adults found no gain and more bleeding.
Is NAD+ a Peptide? No. It Is a Coenzyme Built From Two Nucleotides, and the Peptide Label Comes From the Clinic, Not the Chemistry
Is NAD+ a peptide? No. NAD+ is a coenzyme built from two nucleotides. What NAD+ is used for, what IV NAD+ studies found, and how it differs from SS-31.